These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31554385)

  • 1. PIK3CA and PTEN Genes Expressions in Breast Cancer.
    Alowiri NH; Hanafy SM; Haleem RA; Abdellatif A
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2841-2846. PubMed ID: 31554385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer.
    Loibl S; Darb-Esfahani S; Huober J; Klimowicz A; Furlanetto J; Lederer B; Hartmann A; Eidtmann H; Pfitzner B; Fasching PA; Tiemann K; Jackisch C; Mehta K; von Minckwitz G; Untch M; Denkert C
    Clin Cancer Res; 2016 Jun; 22(11):2675-83. PubMed ID: 26758558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opposite Prognostic Impact of Single PTEN-loss and
    Lazaridis G; Kotoula V; Vrettou E; Kostopoulos I; Manousou K; Papadopoulou K; Giannoulatou E; Bobos M; Sotiropoulou M; Pentheroudakis G; Efstratiou I; Papoudou-Bai A; Psyrri A; Christodoulou C; Gogas H; Koutras A; Timotheadou E; Pectasides D; Zagouri F; Fountzilas G
    Cancer Genomics Proteomics; 2019; 16(3):195-206. PubMed ID: 31018950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
    Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
    Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression.
    Kechagioglou P; Papi RM; Provatopoulou X; Kalogera E; Papadimitriou E; Grigoropoulos P; Nonni A; Zografos G; Kyriakidis DA; Gounaris A
    Anticancer Res; 2014 Mar; 34(3):1387-400. PubMed ID: 24596386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Role of PTEN Gene Expression and Length of Survival of Breast Cancer Patients in the North East of Iran.
    Golmohammadi R; Rakhshani MH; Moslem AR; Pejhan A
    Asian Pac J Cancer Prev; 2016; 17(S3):305-9. PubMed ID: 27165243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.
    Arthur LM; Turnbull AK; Renshaw L; Keys J; Thomas JS; Wilson TR; Lackner MR; Sims AH; Dixon JM
    Breast Cancer Res Treat; 2014 Aug; 147(1):211-9. PubMed ID: 25104442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
    Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [PIK3CA mutation is an independent indicator of malignant phenotype and prognosis in breast cancer].
    Li SY; Wang W; Li JM; Wang Z; Wen RY; Chen J; Miao XT
    Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):605-8. PubMed ID: 22325221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of LncRNA-GACAT3 with MRI features of breast cancer and its molecular mechanism.
    Hu H; Wang Y; Zhang T; Zhang C; Liu Y; Li G; Zhou D; Lu S
    J BUON; 2019; 24(6):2377-2384. PubMed ID: 31983109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
    Saintigny P; Mitani Y; Pytynia KB; Ferrarotto R; Roberts DB; Weber RS; Kies MS; Maity SN; Lin SH; El-Naggar AK
    Cancer; 2018 Sep; 124(18):3693-3705. PubMed ID: 30289966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
    Rimawi MF; De Angelis C; Contreras A; Pareja F; Geyer FC; Burke KA; Herrera S; Wang T; Mayer IA; Forero A; Nanda R; Goetz MP; Chang JC; Krop IE; Wolff AC; Pavlick AC; Fuqua SAW; Gutierrez C; Hilsenbeck SG; Li MM; Weigelt B; Reis-Filho JS; Kent Osborne C; Schiff R
    Breast Cancer Res Treat; 2018 Feb; 167(3):731-740. PubMed ID: 29110152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.
    Sueta A; Yamamoto Y; Yamamoto-Ibusuki M; Hayashi M; Takeshita T; Yamamoto S; Iwase H
    PLoS One; 2014; 9(12):e116054. PubMed ID: 25542038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
    Tserga A; Chatziandreou I; Michalopoulos NV; Patsouris E; Saetta AA
    Virchows Arch; 2016 Jul; 469(1):35-43. PubMed ID: 27059323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer.
    Teo K; Gómez-Cuadrado L; Tenhagen M; Byron A; Rätze M; van Amersfoort M; Renes J; Strengman E; Mandoli A; Singh AA; Martens JH; Stunnenberg HG; van Diest PJ; Brunton VG; Derksen PWB
    Sci Rep; 2018 Oct; 8(1):15454. PubMed ID: 30337563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases.
    Michelucci A; Di Cristofano C; Lami A; Collecchi P; Caligo A; Decarli N; Leopizzi M; Aretini P; Bertacca G; Porta RP; Ricci S; Della Rocca C; Stanta G; Bevilacqua G; Cavazzana A
    Diagn Mol Pathol; 2009 Dec; 18(4):200-5. PubMed ID: 19861897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes.
    Boyault S; Drouet Y; Navarro C; Bachelot T; Lasset C; Treilleux I; Tabone E; Puisieux A; Wang Q
    Breast Cancer Res Treat; 2012 Feb; 132(1):29-39. PubMed ID: 21512767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of PIK3CA mutations and PTEN expression on the effect of neoadjuvant therapy for postmenopausal luminal breast cancer patients.
    Hayama S; Nakamura R; Ishige T; Sangai T; Sakakibara M; Fujimoto H; Ishigami E; Masuda T; Nakagawa A; Teranaka R; Ota S; Itoga S; Yamamoto N; Nagashima T; Otsuka M
    BMC Cancer; 2023 Apr; 23(1):384. PubMed ID: 37106324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.
    Hohensee I; Lamszus K; Riethdorf S; Meyer-Staeckling S; Glatzel M; Matschke J; Witzel I; Westphal M; Brandt B; Müller V; Pantel K; Wikman H
    Am J Pathol; 2013 Jul; 183(1):83-95. PubMed ID: 23665199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.